Kura Oncology reported Q4 2025 net product revenue of USD 2.1 million from the first five weeks of commercial sales following the November 13 FDA approval of its menin inhibitor KOMZIFTI for adults with relapsed or refractory NPM1-mutated AML. Q4 collaboration revenue was USD 15.2 million. Q4 R&D expenses were USD 64.4 million and SG&A expenses were USD 39.1 million, with a Q4 net loss of USD 81.0 million and net loss per share of USD 0.92. For FY 2025, Kura Oncology posted total revenue of USD 67.5 million, including USD 65.4 million in collaboration revenue and USD 2.1 million in net product revenue. FY 2025 R&D expenses were USD 251.1 million and SG&A expenses were USD 120.0 million, with a FY net loss of USD 278.7 million and net loss per share of USD 3.18. Kura Oncology ended 2025 with USD 667.2 million in cash, cash equivalents and short-term investments and said this is expected to fund its operating plan into Q4 2027; together with USD 180 million in anticipated Kyowa Kirin collaboration payments, it expects to fund its ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 frontline trial anticipated in 2028. Business updates included early commercial momentum for KOMZIFTI, rapid payer coverage with about 80% of private payers establishing published coverage policies within the first 90 days aligned with the label, NCCN guideline inclusion as a Category 2A option, Orange Book patent listings extending to July 2044, and progress across clinical programs including initiation of KOMET-017 Phase 3 frontline trials and FIT-001 Phase 1b dose expansion for darlifarnib plus cabozantinib in advanced renal cell carcinoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050631PRIMZONEFULLFEED9666239) on March 05, 2026, and is solely responsible for the information contained therein.